CA3202364A1 - Dsg2 compositions and methods for the treatment of covid-19 - Google Patents
Dsg2 compositions and methods for the treatment of covid-19Info
- Publication number
- CA3202364A1 CA3202364A1 CA3202364A CA3202364A CA3202364A1 CA 3202364 A1 CA3202364 A1 CA 3202364A1 CA 3202364 A CA3202364 A CA 3202364A CA 3202364 A CA3202364 A CA 3202364A CA 3202364 A1 CA3202364 A1 CA 3202364A1
- Authority
- CA
- Canada
- Prior art keywords
- dsg2
- isolated polypeptide
- protein
- covid
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063125583P | 2020-12-15 | 2020-12-15 | |
| US63/125,583 | 2020-12-15 | ||
| US202163274715P | 2021-11-02 | 2021-11-02 | |
| US63/274,715 | 2021-11-02 | ||
| PCT/US2021/063433 WO2022132854A1 (en) | 2020-12-15 | 2021-12-15 | Dsg2 compositions and methods for the treatment of covid-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3202364A1 true CA3202364A1 (en) | 2022-06-23 |
Family
ID=79425717
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3202364A Pending CA3202364A1 (en) | 2020-12-15 | 2021-12-15 | Dsg2 compositions and methods for the treatment of covid-19 |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP4263588A1 (https=) |
| JP (1) | JP2024500250A (https=) |
| KR (1) | KR20230120141A (https=) |
| AU (1) | AU2021400845A1 (https=) |
| CA (1) | CA3202364A1 (https=) |
| IL (1) | IL303444A (https=) |
| MX (1) | MX2023006704A (https=) |
| TW (1) | TW202237634A (https=) |
| WO (1) | WO2022132854A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2024005327A (es) * | 2021-11-02 | 2024-05-21 | Arvada Therapeutics Inc | Composiciones y metodos de dsg2. |
| CN116458893A (zh) * | 2023-04-19 | 2023-07-21 | 电子科技大学 | 一种covid-19后心肌缺血的早期筛查方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100316347B1 (ko) | 1998-09-15 | 2002-08-27 | 한미약품(주) | 대장균엔테로톡신ⅱ신호펩티드의변형체와인체성장호르몬의융합단백질을발현하는재조합미생물및그를이용한인체성장호르몬의제조방법 |
| DE10057397A1 (de) | 2000-11-18 | 2002-05-23 | Hella Kg Hueck & Co | Vorrichtung zur Ölstandsmessung |
| US20100303723A1 (en) * | 2006-11-20 | 2010-12-02 | Massachusetts Institute Of Technology | Drug delivery systems using fc fragments |
| US20190353652A1 (en) * | 2017-01-13 | 2019-11-21 | The Hospital For Sick Children | Method for Diagnosis of Arrhythmogenic Right Ventricular Cardiomyopathy |
-
2021
- 2021-12-15 WO PCT/US2021/063433 patent/WO2022132854A1/en not_active Ceased
- 2021-12-15 IL IL303444A patent/IL303444A/en unknown
- 2021-12-15 MX MX2023006704A patent/MX2023006704A/es unknown
- 2021-12-15 EP EP21841114.8A patent/EP4263588A1/en active Pending
- 2021-12-15 AU AU2021400845A patent/AU2021400845A1/en active Pending
- 2021-12-15 TW TW110146991A patent/TW202237634A/zh unknown
- 2021-12-15 JP JP2023560254A patent/JP2024500250A/ja active Pending
- 2021-12-15 KR KR1020237024240A patent/KR20230120141A/ko active Pending
- 2021-12-15 CA CA3202364A patent/CA3202364A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2023006704A (es) | 2023-06-20 |
| WO2022132854A1 (en) | 2022-06-23 |
| JP2024500250A (ja) | 2024-01-05 |
| KR20230120141A (ko) | 2023-08-16 |
| AU2021400845A1 (en) | 2023-07-13 |
| TW202237634A (zh) | 2022-10-01 |
| IL303444A (en) | 2023-08-01 |
| EP4263588A1 (en) | 2023-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9932377B2 (en) | Mitochondrial targeting and therapeutic use thereof | |
| CN107921085B (zh) | 用于治疗衰老相关病症的方法和组合物 | |
| KR20150121715A (ko) | Ｃｓｆ１ 치료제 | |
| EA009938B1 (ru) | ЛЕЧЕНИЕ ПОЧЕЧНОЙ НЕДОСТАТОЧНОСТИ С ПРИМЕНЕНИЕМ ИНТЕРФЕРОНА-β | |
| CN105705160B (zh) | Il-22二聚体在制备用于治疗胰腺炎的药物中的用途 | |
| US10034915B2 (en) | Small heat shock proteins and active fragments thereof as a therapy for inflammation and ischemia | |
| CA3202364A1 (en) | Dsg2 compositions and methods for the treatment of covid-19 | |
| CN119548617B (zh) | 重组xvii型人源化胶原蛋白的新用途 | |
| CN111423502A (zh) | 多肽、其衍生物及其在制备抗肺纤维化的药物中的应用 | |
| KR102569658B1 (ko) | 컨쥬게이트 c1 에스테라제 억제제 및 그의 용도 | |
| US20240043495A1 (en) | Dsg2 compositions and methods for the treatment of covid-19 | |
| CA2891386A1 (en) | Compositions and methods for the treatment of ectodermal dysplasia | |
| JP2014505655A (ja) | Ｎｄ２ペプチドおよび神経疾患の治療方法 | |
| US20240279304A1 (en) | Dsg2 compositions and methods | |
| US10160791B2 (en) | Protamine in treatment of neuronal injuries | |
| CN116648255A (zh) | 用于治疗covid-19的dsg2组合物和方法 | |
| JP6416480B2 (ja) | 関節リウマチまたはその関連疾患の予防または治療剤 | |
| JP4256497B2 (ja) | 血管炎治療剤 | |
| WO2022020544A1 (en) | Method of treating an inflammatory condition | |
| GB2241891A (en) | Tumour necrosis factor compositions for treating inflammatory disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240910 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240910 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240910 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250929 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250929 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20251211 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20251211 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251211 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260209 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20260209 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260209 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260209 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260209 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260210 |